LeMaitre Vascular, Inc. (LMAT)

82.55 -0.81 (-0.97%) USD  |  NASDAQ  |  Dec 12, 10:08
More

LeMaitre Vascular Research and Development Expense (Quarterly): 2.97M for Sept. 30, 2025

Research and Development Expense (Quarterly) Chart

View Research and Development Expense (Quarterly) for LMAT.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Research and Development Expense (Quarterly) Chart
Start Trial

Historical Data

View Historical Data
Start Trial

R&D Expense Definition

View R&D Expense Definition
Start Trial

R&D expense is a line item from many companies' income statements.

Read full definition.

Research and Development Expense (Quarterly) Range, Past 5 Years

View Research and Development Expense (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Research and Development Expense (Quarterly) Benchmarks

View Research and Development Expense (Quarterly) Benchmarks
Start Trial
Baxter International, Inc. 115.00M
Integra LifeSciences Holdings Corp. 20.42M
ResMed, Inc. 87.32M
Perspective Therapeutics, Inc. 19.56M
Xtant Medical Holdings, Inc. 0.634M